🔎 Trials Near Me

Почетна › Множен миелом › Индијана

Клинички испитувања за Множен миелом во Индијана

19 студии за Множен миелом бараат учесници на локации во Индијана.

Градови во Индијана

Официјален текст на студијата (англиски)

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

  • Study Site 101, Fort Wayne
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT07582432

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

  • Indiana University, Indianapolis
Се регрутираФаза 4
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT05201781

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  • Franciscan Health, Indianapolis
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07518186

A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

  • Genesis Medical Research, Dyer
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 24.9.2026 · NCT07477587

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

  • Community Health Network (The University of Texas MD Anderson Cancer Center), Indianapolis
Се регрутираФаза 2
Возраст 12 и постари · Сите полови · Ажурирано 22.9.2026 · NCT02693535

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

  • Fort Wayne Medical Oncology And Hematology /ID# 278141, Fort Wayne
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07095452

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  • Indiana University Health Arnett, Inc., Lafayette
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 21.9.2026 · NCT07648264

Collection of Tissue Samples for Cancer Research

  • Indiana University - Purdue, Indianapolis
Се регрутираНабљудувачка студија
2 Months · Сите полови · Ажурирано 16.9.2026 · NCT00900198

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  • Community Health Network, Inc., Indianapolis
  • Community Health Network, Inc., Indianapolis
  • Community Health Network, Inc., Indianapolis
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 24.8.2026 · NCT06152575

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

  • IU Health North Hospital, Carmel
  • Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
  • IU Health Methodist Hospital, Indianapolis
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 19.8.2026 · NCT04566328

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

  • Indiana University, Indianapolis
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 12.8.2026 · NCT07280013

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  • Indiana University Health, Indianapolis
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 6.8.2026 · NCT07284758

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • Fort Wayne Medical Oncology And Hematology /ID# 268179, Fort Wayne
  • Franciscan St. Francis Health /ID# 280928, Indianapolis
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 13.7.2026 · NCT05650632

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

  • Indiana University Health Simon Cancer Center, Indianapolis
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 8.7.2026 · NCT05137054

Integrated Cancer Repository for Cancer Research

  • Parkview Research Center, Fort Wayne
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Возраст од 19 до 110 · Сите полови · Ажурирано 29.6.2026 · NCT02012699

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

  • Community Health Network, Indianapolis
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 24.6.2026 · NCT04068597

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

  • IU Health North Hospital, Carmel
  • Northwest Cancer Center - Main Campus, Crown Point
  • Northwest Oncology LLC, Dyer
  • и уште 8
Се регрутираФаза 3
Сите возрасти · Сите полови · Ажурирано 10.6.2026 · NCT05561387

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • Baptist Floyd, New Albany
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Возраст 40 и постари · Сите полови · Ажурирано 20.1.2026 · NCT05366881

The Indiana Myeloma Registry

  • Indiana University Simon Cancer Center, Indianapolis
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 10.11.2025 · NCT03616483

Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.